Disease relevance of Vectorcardiography

• Quantitative assessment of myocardial ischemia and necrosis by continuous vectorcardiography and measurement of creatine kinase release in patients [1].
• Accordingly, 25 adults with classic Steinert's disease underwent electrocardiography, 24-hour ambulatory electrocardiography, vectorcardiography, chest x-rays, echocardiography, electrophysiologic studies, and technetium-99m angiography [2].
• Myocardial infarction diagnosis with body surface potential mapping, electrocardiography, vectorcardiography and thallium-201 scintigraphy: a correlative study with left ventriculography [3].

High impact information on Vectorcardiography

• METHODS AND RESULTS: The methods evaluated were: clinical risk estimation at hospital admission, continuous ST analysis with computerized vectorcardiography for 24 h and serial measurements of creatinine kinase-MB for 48 h [4].
• OBJECTIVES: To evaluate tissue plasminogen activator (tPA) activity as a measure of fibrinolytic response to treatment with streptokinase (SK) and to relate this to the effect of pretreatment SK antibodies and to successful reperfusion assessed by continuous computerized vectorcardiography (VCG) [5].
• Ischaemia monitoring with on-line vectorcardiography during dobutamine stress echocardiography in patients after an episode of unstable coronary artery disease [6].
• Vectorcardiography and COPD [7].
• Clinical vectorcardiography in adults. Part 2 [8].

Chemical compound and disease context of Vectorcardiography

• Myocardial infarction size and location: a comparative study of epicardial isopotential mapping, thallium-201 scintigraphy, electrocardiography and vectorcardiography [9].

Associations of Vectorcardiography with chemical compounds

• AIM: To compare the electrophysiological effects of two contrast media (CM), the non-ionic dimer iodixanol and the ionic dimer ioxaglate using computerised dynamic vectorcardiography (VCG) during coronary angiography [10].
• Ischaemia was monitored using continuous vectorcardiography during the 4 h of treatment and during the subsequent 4 h after inogatran infusion had been stopped, to detect any increase in ischaemic events after the period of treatment [11].

Gene context of Vectorcardiography

• Two-year dynamics of vectorcardiography parameters in patients with primary pulmonary hypertension [12].
• Value of vectorcardiography in predicting progress in dilated cardiomyopathy [13].

References